vs
CHAMPIONS ONCOLOGY, INC.（CSBR）与Rocky Mountain Chocolate Factory, Inc.（RMCF）财务数据对比。点击上方公司名可切换其他公司
CHAMPIONS ONCOLOGY, INC.的季度营收约是Rocky Mountain Chocolate Factory, Inc.的2.0倍（$15.0M vs $7.5M），CHAMPIONS ONCOLOGY, INC.净利率更高（1.8% vs -2.1%，领先3.8%），CHAMPIONS ONCOLOGY, INC.同比增速更快（11.5% vs -4.4%），Rocky Mountain Chocolate Factory, Inc.自由现金流更多（$-1.3M vs $-2.0M），过去两年CHAMPIONS ONCOLOGY, INC.的营收复合增速更高（11.8% vs 1.9%）
冠军肿瘤学公司是一家成立于2007年的美国科技企业，由约翰霍普金斯大学肿瘤学家David Sidransky博士创立。该公司开发名为TumorGrafts的小鼠模型（又称小鼠化身），可用于测试多种化疗方案、靶向药物与单克隆抗体，帮助为癌症患者筛选潜在的可行治疗方案。
落基山巧克力厂是美国知名巧克力企业，同时开展国际特许经营业务，集糖果生产与零售运营于一体，总部位于美国科罗拉多州杜兰戈，除美国本土门店外，在巴拿马、菲律宾也设有经营网点。
CSBR vs RMCF — 直观对比
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $15.0M | $7.5M |
| 净利润 | $268.0K | $-155.0K |
| 毛利率 | 51.7% | 34.0% |
| 营业利润率 | 1.2% | 1.1% |
| 净利率 | 1.8% | -2.1% |
| 营收同比 | 11.5% | -4.4% |
| 净利润同比 | -63.2% | 81.7% |
| 每股收益（稀释后） | $0.02 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $15.0M | $7.5M | ||
| Q3 25 | $14.0M | $6.8M | ||
| Q2 25 | $12.4M | $6.4M | ||
| Q1 25 | $17.0M | $8.9M | ||
| Q4 24 | $13.5M | $7.9M | ||
| Q3 24 | $14.1M | $6.4M | ||
| Q2 24 | $14.0M | $6.4M | ||
| Q1 24 | $12.0M | $7.3M |
| Q4 25 | $268.0K | $-155.0K | ||
| Q3 25 | $-436.0K | $-662.0K | ||
| Q2 25 | $-1.8M | $-324.0K | ||
| Q1 25 | $4.5M | $-2.9M | ||
| Q4 24 | $728.0K | $-847.0K | ||
| Q3 24 | $1.3M | $-722.0K | ||
| Q2 24 | $-109.0K | $-1.7M | ||
| Q1 24 | $-2.5M | $-1.6M |
| Q4 25 | 51.7% | 34.0% | ||
| Q3 25 | 42.9% | 23.6% | ||
| Q2 25 | 41.1% | 31.1% | ||
| Q1 25 | 61.2% | 10.8% | ||
| Q4 24 | 44.9% | 23.4% | ||
| Q3 24 | 49.7% | 31.8% | ||
| Q2 24 | 48.2% | 12.8% | ||
| Q1 24 | 34.7% | 24.3% |
| Q4 25 | 1.2% | 1.1% | ||
| Q3 25 | -3.8% | -7.0% | ||
| Q2 25 | -16.2% | -2.3% | ||
| Q1 25 | 26.4% | -30.3% | ||
| Q4 24 | 5.4% | -8.9% | ||
| Q3 24 | 9.5% | -14.3% | ||
| Q2 24 | -1.9% | -25.4% | ||
| Q1 24 | -21.4% | -21.7% |
| Q4 25 | 1.8% | -2.1% | ||
| Q3 25 | -3.1% | -9.7% | ||
| Q2 25 | -14.9% | -5.1% | ||
| Q1 25 | 26.4% | -32.5% | ||
| Q4 24 | 5.4% | -10.7% | ||
| Q3 24 | 9.3% | -11.3% | ||
| Q2 24 | -0.8% | -25.9% | ||
| Q1 24 | -21.1% | -21.9% |
| Q4 25 | $0.02 | $-0.02 | ||
| Q3 25 | $-0.03 | $-0.09 | ||
| Q2 25 | $-0.12 | $-0.04 | ||
| Q1 25 | $0.31 | $-0.38 | ||
| Q4 24 | $0.05 | $-0.11 | ||
| Q3 24 | $0.09 | $-0.11 | ||
| Q2 24 | $-0.01 | $-0.26 | ||
| Q1 24 | $-0.19 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $641.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.2M | $6.0M |
| 总资产 | $30.2M | $20.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $8.5M | $641.0K | ||
| Q3 25 | $10.3M | $2.0M | ||
| Q2 25 | $9.8M | $893.0K | ||
| Q1 25 | $3.2M | $720.0K | ||
| Q4 24 | $2.8M | $1.1M | ||
| Q3 24 | $2.9M | $973.0K | ||
| Q2 24 | $2.6M | $637.0K | ||
| Q1 24 | $4.5M | $2.1M |
| Q4 25 | $4.2M | $6.0M | ||
| Q3 25 | $3.5M | $6.1M | ||
| Q2 25 | $3.8M | $6.7M | ||
| Q1 25 | $5.5M | $7.0M | ||
| Q4 24 | $681.0K | $9.8M | ||
| Q3 24 | $-332.0K | $10.5M | ||
| Q2 24 | $-1.9M | $9.0M | ||
| Q1 24 | $-2.1M | $10.6M |
| Q4 25 | $30.2M | $20.7M | ||
| Q3 25 | $30.5M | $22.3M | ||
| Q2 25 | $32.3M | $20.1M | ||
| Q1 25 | $30.6M | $21.2M | ||
| Q4 24 | $25.2M | $21.6M | ||
| Q3 24 | $24.9M | $21.1M | ||
| Q2 24 | $26.1M | $19.0M | ||
| Q1 24 | $26.8M | $20.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $-1.3M |
| 自由现金流率自由现金流/营收 | -13.1% | -16.9% |
| 资本支出强度资本支出/营收 | 1.6% | 0.5% |
| 现金转化率经营现金流/净利润 | -6.47× | — |
| 过去12个月自由现金流最近4个季度 | $5.6M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-1.7M | $-1.2M | ||
| Q3 25 | $600.0K | $-488.0K | ||
| Q2 25 | $6.9M | $350.0K | ||
| Q1 25 | $490.0K | $1.2M | ||
| Q4 24 | $-283.0K | $-2.1M | ||
| Q3 24 | $311.0K | $-3.5M | ||
| Q2 24 | $-1.8M | $-2.2M | ||
| Q1 24 | $-919.0K | $129.0K |
| Q4 25 | $-2.0M | $-1.3M | ||
| Q3 25 | $554.0K | $-544.0K | ||
| Q2 25 | $6.6M | $182.0K | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | $-4.6M | ||
| Q2 24 | $-1.8M | $-2.6M | ||
| Q1 24 | $-1.0M | $-352.3K |
| Q4 25 | -13.1% | -16.9% | ||
| Q3 25 | 4.0% | -8.0% | ||
| Q2 25 | 53.5% | 2.9% | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | -72.6% | ||
| Q2 24 | -13.0% | -40.2% | ||
| Q1 24 | -8.4% | -4.9% |
| Q4 25 | 1.6% | 0.5% | ||
| Q3 25 | 0.3% | 0.8% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | 17.5% | ||
| Q2 24 | 0.0% | 6.5% | ||
| Q1 24 | 0.8% | 6.6% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
RMCF
| Manufacturing | $5.9M | 78% |
| Transferred At Point In Time | $1.2M | 16% |
| Other | $414.0K | 5% |
